Garnero P, Delmas P D
Institut National de la Santé et de la Recherche Médicale, Hôpital E. Herriot, Lyon, France.
Endocrinol Metab Clin North Am. 1998 Jun;27(2):303-23. doi: 10.1016/s0889-8529(05)70007-4.
The recent discovery of specific and sensitive biochemical markers reflecting the overall rate of bone formation and bone resorption has markedly improved the noninvasive assessment of bone turnover in various metabolic bone diseases, especially in osteoporosis. The immunoassay of human osteocalcin, recognizing the intact molecule and its major proteolytic fragment, and assays for bone alkaline phosphatase and the intact form of the N-terminal extension propeptide of type I collagen are currently the most sensitive markers for assessing bone formation. The best indices of bone resorption are the new immunoassays for pyridinoline cross-links and type I collagen-related peptides in urine and, recently, in serum. Several studies indicate that screening for these bone markers may be useful for improving the prognostic assessment of postmenopausal women in combination with bone mass measurement, that is, their risk for osteoporosis and, ultimately, for fractures and to monitor rapidly the efficacy of antiresorptive drugs.
